| A178 |
Metheresis patent anti-Met Biosimilar（Anti-HGFR / c-Met Reference Antibody）
Featured
|
|
|
| A179 |
Derlotuximab Biosimilar（Anti-Histone H1 Reference Antibody）
Featured
|
|
|
| A180 |
Immunomedics patent anti-Histone H2B Biosimilar（Anti-Histone H2B Reference Antibody）
Featured
|
|
|
| A181 |
Immunomedics patent anti-Histone H3 Biosimilar（Anti-Histone H3 Reference Antibody）
Featured
|
|
|
| A182 |
Immunomedics patent anti-Histone H4 Biosimilar（Anti-Histone H4 Reference Antibody）
Featured
|
|
|
| A183 |
IMMU-114 Biosimilar（Anti-HLA-DR Reference Antibody）
Featured
|
|
|
| A184 |
Galegenimab Biosimilar（Anti-HTRA1 Reference Antibody）
Featured
|
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research. |
.png)
|
| A185 |
Bersanlimab Biosimilar（Anti-ICAM1 / CD54 Reference Antibody）
Featured
|
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. |
.png)
|
| A186 |
Forerunner patent anti-ICAM-3 Biosimilar（Anti-ICAM3 / CD50 Reference Antibody）
Featured
|
|
|
| A187 |
Vopratelimab Biosimilar（Anti-ICOS / CD278 Reference Antibody）
Featured
|
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response. |
.png)
|
| A188 |
MEDI-570 Biosimilar（Anti-ICOS / CD278 Reference Antibody）
Featured
|
|
|
| A189 |
Alomfilimab Biosimilar（Anti-ICOS / CD278 Reference Antibody）
Featured
|
Alomfilimab(KY-1044; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response. |
.png)
|
| A190 |
Feladilimab Biosimilar（Anti-ICOS / CD278 Reference Antibody）
Featured
|
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer. |
.png)
|
| A191 |
LIMR patent anti-IDO2 Biosimilar(Anti-IDO2 Reference Antibody)
Featured
|
|
|
| A192 |
Sifalimumab Biosimilar(Anti-IFNa1 Reference Antibody)
Featured
|
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research. |
.png)
|
| A193 |
Rontalizumab Biosimilar(Anti-IFNa1 Reference Antibody)
Featured
|
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus. |
.png)
|
| A194 |
Baylor patent anti-IFN alpha Biosimilar(Anti-IFNa1 Reference Antibody)
Featured
|
|
|
| A195 |
Chinese CDC patent anti-Interferon Alpha Biosimilar(Anti-IFNa1 Reference Antibody)
Featured
|
|
|
| A196 |
Anifrolumab Biosimilar(Anti-IFNAR1 Reference Antibody)
Featured
|
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research. |
.png)
|
| A197 |
Medarex patent anti-IFNAR-1 Biosimilar(Anti-IFNAR1 Reference Antibody)
Featured
|
|
|
| A198 |
Emapalumab Biosimilar（Anti-IFNg Reference Antibody）
Featured
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH). |
.png)
|
| A199 |
Fontolizumab Biosimilar(Anti-IFNg Reference Antibody)
Featured
|
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease. |
.png)
|
| A200 |
AMG-811 Biosimilar(Anti-IFNg Reference Antibody)
Featured
|
|
|
| A201 |
Talizumab Biosimilar(Anti-IgE Reference Antibody)
Featured
|
Talizumab (TNX 901) is an anti-IgE humanized IgG1 monoclonal antibody. |
.png)
|
| A202 |
Quilizumab Biosimilar(Anti-IgE (M1 prime) Reference Antibody)
Featured
|
Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody. Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. Quilizumab has the potantial for the asthma research. |
.png)
|
| A203 |
Xentuzumab Biosimilar(Anti-IGF-1 Reference Antibody)
Featured
|
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation. |
.png)
|
| A204 |
Teprotumumab Biosimilar(Anti-IGF1R / CD221 Reference Antibody)
Featured
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research. |
.png)
|
| A205 |
Robatumumab Biosimilar(Anti-IGF1R / CD221 Reference Antibody)
Featured
|
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research. |
.png)
|
| A206 |
Lonigutamab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC). |
.png)
|
| A207 |
Ganitumab Biosimilar (Anti-IGF1R / CD221 Reference Antibody )
Featured
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer. |
.png)
|
